TY - JOUR
T1 - Update on pediatric gastroparesis
T2 - A review of the published literature and recommendations for future research
AU - Kovacic, Katja
AU - Elfar, Walaa
AU - Rosen, John M.
AU - Yacob, Desale
AU - Raynor, Jennifer
AU - Mostamand, Shikib
AU - Punati, Jaya
AU - Fortunato, John E.
AU - Saps, Miguel
N1 - Funding Information:
This manuscript was reviewed and endorsed by the American Neurogastroenterology and Motility Society. The initial sorting of studies for inclusion criteria was assisted by the use of Rayyan software, a web and mobile app for systematic review. KK provides consultancy service for Takeda pharmaceuticals. JP provides consultancy services to QOL medical and MCkesson. JF provides consultancy services to Abbotts. Those consultancy services are not relevant to this paper. The rest of the authors did not have any consultancy services to disclose.
Publisher Copyright:
© 2019 John Wiley & Sons Ltd
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Background: Due to scarcity of scientific literature on pediatric gastroparesis, there is a need to summarize current evidence and identify areas requiring further research. The aim of this study was to provide an evidence-based review of the available literature on the prevalence, pathogenesis, clinical presentation, diagnosis, treatment, and outcomes of pediatric gastroparesis. Methods: A search of the literature was performed using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines with the following databases: PubMed, EMBASE, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, and Web of Science. Two independent reviewers screened abstracts for eligibility. Key Results: Our search yielded 1085 original publications, 135 of which met inclusion criteria. Most articles were of retrospective study design. Only 12 randomized controlled trials were identified, all of which were in infants. The prevalence of pediatric gastroparesis is unknown. Gastroparesis may be suspected based on clinical symptoms although these are often non-specific. The 4-hour nuclear scintigraphy scan remains gold standard for diagnosis despite lack of pediatric normative comparison data. Therapeutic approaches include dietary modifications, prokinetic drugs, and postpyloric enteral tube feeds. For refractory cases, intrapyloric botulinum toxin and surgical interventions such as gastric electrical stimulation may be warranted. Most interventions still lack rigorous supportive data. Conclusions: Diagnosis and treatment of pediatric gastroparesis are challenging due to paucity of published evidence. Larger and more rigorous clinical trials are necessary to improve outcomes.
AB - Background: Due to scarcity of scientific literature on pediatric gastroparesis, there is a need to summarize current evidence and identify areas requiring further research. The aim of this study was to provide an evidence-based review of the available literature on the prevalence, pathogenesis, clinical presentation, diagnosis, treatment, and outcomes of pediatric gastroparesis. Methods: A search of the literature was performed using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines with the following databases: PubMed, EMBASE, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, and Web of Science. Two independent reviewers screened abstracts for eligibility. Key Results: Our search yielded 1085 original publications, 135 of which met inclusion criteria. Most articles were of retrospective study design. Only 12 randomized controlled trials were identified, all of which were in infants. The prevalence of pediatric gastroparesis is unknown. Gastroparesis may be suspected based on clinical symptoms although these are often non-specific. The 4-hour nuclear scintigraphy scan remains gold standard for diagnosis despite lack of pediatric normative comparison data. Therapeutic approaches include dietary modifications, prokinetic drugs, and postpyloric enteral tube feeds. For refractory cases, intrapyloric botulinum toxin and surgical interventions such as gastric electrical stimulation may be warranted. Most interventions still lack rigorous supportive data. Conclusions: Diagnosis and treatment of pediatric gastroparesis are challenging due to paucity of published evidence. Larger and more rigorous clinical trials are necessary to improve outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85076748651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076748651&partnerID=8YFLogxK
U2 - 10.1111/nmo.13780
DO - 10.1111/nmo.13780
M3 - Review article
C2 - 31854057
AN - SCOPUS:85076748651
SN - 1350-1925
VL - 32
JO - Neurogastroenterology and Motility
JF - Neurogastroenterology and Motility
IS - 3
M1 - e13780
ER -